CSL (ASX:CSL) Could Be 4% Undervalued As Board Changes Put Governance In Focus

Board succession at CSL puts governance in the spotlight

CSL (ASX:CSL) has flagged a major board reshuffle, with Chair Dr Brian McNamee AO set to retire in March 2027 and Gordon Naylor elected as his successor.

The handover coincides with Deborah Waterhouse’s arrival as Chief Executive, while Carolyn Hewson AO has been appointed Senior Independent Director. This is focusing investor attention on how this refreshed leadership bench may influence long term oversight.

CSL’s recent governance update lands after a powerful run in the share price, with a 30 day share price return of 13.28% and a 90 day share price return of 53.11%, taking the stock to A$202.4.

Momentum has picked up this year, with a year to date share price return of 17.70%. However, the 3 year total shareholder return declined 14.92% and the 5 year total shareholder return fell 28.31%. This keeps long term holders focused on whether this leadership reset shifts how the business is managed and valued.

Scan beyond CSL and see how other high quality healthcare groups stack up on governance, balance sheet strength and recent price moves using our curated list of 6 resilient stocks with low risk scores.

After CSL’s sharp rally back to A$202.40 and a mixed track record for longer term holders, the real puzzle now is whether meaningful upside still lies ahead or if most of the easy gains are already in the rear view mirror.

Most Popular Narrative: 4% Undervalued

On the numbers in front of you, CSL’s widely followed narrative pegs fair value at A$210.00, a touch above the last close at A$202.40. This keeps the focus on whether the current governance reshuffle can support that valuation case over time.

CSL is one of Australia’s highest-quality businesses and has a long history of delivering strong returns. It is a global leader in plasma therapies, vaccines and biotechnology, with products that are difficult to replicate and protected by strict regulation. Healthcare demand tends to remain resilient regardless of economic conditions.

See why 41 investors see CSL as 4% undervalued.

This narrative, according to danmad, leans heavily on CSL’s position in plasma therapies, vaccines and kidney care. The view is that hard to replicate products, strict regulation and high barriers to entry support pricing power. That can matter for investors weighing the current A$202.40 share price against a fair value view of A$210.00.

Supporters of this thesis point to several structural pillars behind that fair value. These include CSL Behring’s plasma derived medicines, the Seqirus influenza franchise that serves governments, and the Vifor iron deficiency and nephrology unit. They also note plans to expand plasma collection, invest in rare disease therapies and keep lifting manufacturing efficiency.

Others will highlight the trade offs. CSL is currently loss making at the net income line, carries a high level of debt, and forecasts point to revenue growth of 3% per year, which is slower than the wider Australian market at 4.8% per year. In addition, CSL is expected to become profitable in the next 3 years, but its forecast return on equity of 18.6% is flagged as low in that same timeframe, and the 3 year and 5 year total shareholder returns declined 14.92% and 28.31% respectively.

Governance sits in the middle of this valuation debate. The board has 90% independent directors and a good mix of tenures. However, the average board tenure of 2.5 years and six new directors over the past 3 years point to meaningful turnover at the top. Management is considered experienced with an average tenure of 2.6 years, and Gordon Naylor’s total compensation of US$3.53m is described as about average for companies of similar size in Australia, although there is insufficient data to tie that pay directly to performance yet.

On the quantitative side, the model behind this narrative applies a 7.50% discount rate and arrives at a fair value of A$210.00 per share. This places CSL at roughly a 4% discount to that estimate. That sits close to Simply Wall St’s own fair value work, where CSL is described as trading 3.9% below intrinsic value and as good value compared to peers and the Australian Biotechs industry, despite reported losses and a negative return on equity of 18.31% at present.

Result: Fair Value of A$210.00 (UNDERVALUED)

Still, CSL’s loss at the net income line and the recent declines in 3 and 5 year total shareholder returns could easily upset this fair value story.

Find out about the key risks to this CSL narrative.

Next Steps

If this mix of optimism and concern around CSL feels familiar, use it as a prompt to move quickly and test the numbers yourself. To weigh up both the potential upsides and the issues flagged by recent data, start with the 3 key rewards and 1 important warning sign.

Looking for more CSL investment ideas?

If CSL has sharpened your focus on quality, do not stop here. Broaden your watchlist now so you are not chasing the next move after it happens.

• Target potential mispricing by scanning a curated set of high quality value candidates through the 5 high quality undervalued stocks.
• Lock in the appeal of income-focused opportunities by reviewing a hand picked pool of yield heavy contenders using the 5 dividend fortresses.
• Protect your capital first by filtering for financially resilient businesses with stronger balance sheets via the list of solid balance sheet and fundamentals (12 results).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com